Breast Cancer Treatment Market By Drug Type (Chemotherapy Drugs, Hormone Therapy Drugs, Targeted Therapy Drugs, and Other Therapeutic Drugs) Regional Analysis & Forecast - 2026
- OI-21 |
- Published date: Jan, 2019 |
- Oncology/Hematology |
- Pages
Introduction
Breast cancer is the result of uncontrolled cell division of breast cells, most common cells of breast lobule and ducts. It may also affect fatty or connective tissues within the breasts. Breast cancer is most prevalent in women, however, breast cancer in men is rare. It is frequently diagnosed in aged women and one of the leading causes of death among them. Some of the most common types of breast cancer are ductal carcinoma in situ (DCIS), lobular carcinoma and invasive ductal carcinoma Breast cancer is the second most common type of cancer worldwide, affecting nearly 2 million women.
Market Overview
The global breast cancer treatment market was valued at $ XX Mn in 2018 and is forecast to grow at a strong XX% CAGR between 2018 and 2026, resulting in 2026 global sales of $ XX. The market is driven by owing higher incidence rate and diagnostic screening programs. However, access barriers owing to high drug costs are restraining market growth. Prospective development of domestic pharmaceutical companies is providing ample opportunities for the market.
Breast cancer depending on the type, HER2 inhibitor segment is expected to account for the largest share of the Breast cancer market. Rising incidence of HER2 positive breast cancer is the main factor attributed to the development of this segment. There are about one in five women diagnosed with a breast tumor would have HER2 positive cancer. In addition, huge demand from developing markets such as Latin America and the Asia Pacific, are factors boosting the Breast cancer industry.
Key Developments
- FDA recently approved the Investigational New Drug (IND) application for Athenex’s oral form of Eribulin. It is an anticancer drug promoted by Eisai Company under the brand name Halaven and can effectively treat metastatic breast cancer and liposarcoma. The company is allowed to initiate a clinical trial program, which is expected to start in the first half of 2019.
- On 6 May 2019: FDA has approved Kadcyla® (trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (eABC)
Segmentation
The global Breast cancer in the Healthcare market is segmented on the basis of application, end-user, and region.
Based on the Drug Type: Chemotherapy Drugs, Hormone Therapy Drugs, Targeted Therapy Drugs, and Other Therapeutic Drugs.
Based on the region: North America, Asia-Pacific, Europe, and LAMEA. Among that Asia-Pacific held the largest share of the market. The fastest growth in global demand for drugs has encouraged major drug manufacturers to set up facilities for manufacturing and R&D in this region. Initiatives undertaken by various governments to instruct people, raise funds for the disease and create awareness is a factor to drive the regional growth
The key players of the Global Breast cancer market include BioNumerik Pharmaceuticals Inc, Onyx Pharmaceuticals Inc., Celldex Therapeutics., MacroGenics Inc., Genentech, Inc., AbbVie, Inc., AstraZeneca, F. Hoffman-La Roche Pvt. Ltd, Genzyme Corporation, Astellas Pharma Inc., Celgene Corporation and Astellas Pharma Inc
The report covers in-depth analysis of the Global Breast cancer Treatment Market. The report assesses the market products pipeline by stage of development (early development, pre-clinical, clinical and in approval), by Drug Type (Chemotherapy Drugs, Hormone Therapy Drugs, Targeted Therapy Drugs, and Other Therapeutic Drugs). In addition, the report includes key insights on other development activities, including (but not limited to) – licensing (In and Out), collaborations, acquisitions, reimbursement, patent, and regulatory designations.
The report includes in-depth company profiles of key players in Global Breast cancer in the Healthcare Market. The company profile includes key information on the overview, financial highlights, product portfolio, business strategies, and key recent developments.
The report highlights information on emerging companies with potentially disruptive technologies and new market entrants.
Scope:
- Provides detailed analysis of the market structure along with forecast of the various segments and sub-segments of the Global Breast cancer Treatment Market.
- Provides a comparative analysis of key marketed products and pipeline market products.
- Provides key information on players involved in the Global Breast cancer Treatment Market.
- Provides a complete overview of market segments and the regional outlook of Global Breast cancer Treatment Market.
- Provides in-depth coverage of key news related to global Breast cancer in Healthcare Market, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates
-
Data Collation (Primary & Secondary)
-
In-house Estimation (Based on proprietary databases and Models)
-
Market Triangulation
-
Forecasting
-
Market-related information is assembled from both primary and secondary sources.
-
Primary sources involved participants from all global stakeholders such as experts from several related industries and suppliers that have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The participants included are CXOs, VPs, and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.
-
Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications annual reports press releases along with paid sources such as Factiva, OneSource, Bloomberg among others.
-
Top-down and bottom-up approaches: The overall market size was used in the top-down approach to estimate the sizes of other individual submarkets (mentioned in the market segmentation by product, type of manufacturing, and disease) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained.
